MX358613B - Tratamiento de dolor de cabeza por migraña con neurotoxina presinaptica. - Google Patents
Tratamiento de dolor de cabeza por migraña con neurotoxina presinaptica.Info
- Publication number
- MX358613B MX358613B MX2014010983A MX2014010983A MX358613B MX 358613 B MX358613 B MX 358613B MX 2014010983 A MX2014010983 A MX 2014010983A MX 2014010983 A MX2014010983 A MX 2014010983A MX 358613 B MX358613 B MX 358613B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- migraine
- presynaptic neurotoxin
- migraine headaches
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un método para tratar un paciente de dolor de cabeza por migraña, incluyendo síntomas asociados con dolor de cabeza por migraña, tales como vértigo asociada con migraña, que comprende administrar al paciente una cantidad terapéuticamente eficaz de una neurotoxina presináptica de invertebrado, por ejemplo, toxina botulínica en una forma farmacéuticamente segura.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261609817P | 2012-03-12 | 2012-03-12 | |
US13/478,640 US8722060B2 (en) | 2012-05-23 | 2012-05-23 | Method of treating vertigo |
US13/478,828 US8420106B1 (en) | 2012-03-12 | 2012-05-23 | Extramuscular treatment of traumatic-induced migraine headache |
US13/478,922 US20130236446A1 (en) | 2012-03-12 | 2012-05-23 | Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth |
US13/478,602 US8617569B2 (en) | 2012-03-12 | 2012-05-23 | Treatment of migraine headache with diffusion of toxin in non-muscle related foraminal sites |
US13/478,876 US8491917B1 (en) | 2012-03-12 | 2012-05-23 | Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head |
PCT/US2013/000131 WO2013137969A1 (en) | 2012-03-12 | 2013-05-10 | Treatment of migraine headaches with presynaptic neurotoxin |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014010983A MX2014010983A (es) | 2017-07-21 |
MX358613B true MX358613B (es) | 2018-08-27 |
Family
ID=49161648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014010983A MX358613B (es) | 2012-03-12 | 2013-05-10 | Tratamiento de dolor de cabeza por migraña con neurotoxina presinaptica. |
Country Status (9)
Country | Link |
---|---|
US (2) | US20150231068A1 (es) |
EP (2) | EP3257526B1 (es) |
AU (1) | AU2013232758C1 (es) |
CA (1) | CA2867143C (es) |
DK (1) | DK2849781T3 (es) |
ES (2) | ES2759478T3 (es) |
MX (1) | MX358613B (es) |
WO (1) | WO2013137969A1 (es) |
ZA (1) | ZA201406598B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8617571B2 (en) * | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
US9764009B2 (en) * | 2011-06-13 | 2017-09-19 | Allergan, Inc. | Treatment of psychological trauma |
WO2015183044A1 (ko) * | 2014-05-29 | 2015-12-03 | 주식회사 프로셀테라퓨틱스 | 신규한 세포투과성 펩타이드 및 이와 보툴리눔 독소 결합체 및 이들의 용도 |
AU2018237205A1 (en) * | 2017-03-22 | 2019-10-31 | Bonti, Inc. | Botulinum neurotoxins for treating traumatic injuries |
WO2019068888A1 (en) * | 2017-10-06 | 2019-04-11 | Ranoux Daniele | USE OF BOTULINUM TOXIN FOR THE TREATMENT OF SUBJECTIVE ACOUPHENES |
IT201800001119A1 (it) * | 2018-01-16 | 2019-07-16 | Francesco Giuseppe Bono | Metodo regionalizzato e focalizzato di somministrazione di tossina botulinica mediante iniezione intradermica- subdermica-sottocutanea per il trattamento dell’emicrania cronica intrattabile e della cefalea |
WO2021247890A1 (en) * | 2020-06-03 | 2021-12-09 | Miotox, Llc | Zonal and targeted methods and uses for treating a migraine disorder |
JP2024507589A (ja) * | 2021-02-26 | 2024-02-20 | イーオン バイオファーマ インコーポレイテッド | 頭痛の治療に使用するための神経毒素組成物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
ES2238969T3 (es) * | 1994-05-09 | 2005-09-16 | William J. Binder | Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas. |
US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
CA2369810C (en) | 2002-01-30 | 2007-08-07 | 1474791 Ontario Limited | Method of treating pain |
US20050106183A1 (en) | 2002-01-31 | 2005-05-19 | Lamb Gregory B. | Method of treating pain |
JP2006519761A (ja) | 2002-12-20 | 2006-08-31 | ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド | 改善された薬学的ボツリヌス毒素組成物 |
MXPA05009425A (es) | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica. |
US20040204471A1 (en) | 2003-03-20 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents |
WO2004084839A2 (en) * | 2003-03-24 | 2004-10-07 | Cady Roger K | Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8617572B2 (en) * | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
US7270287B2 (en) | 2004-01-06 | 2007-09-18 | Allergan, Inc. | Botulinum toxin treatment for kinesia |
US8497081B2 (en) * | 2004-02-24 | 2013-07-30 | Allergan, Inc. | Botulinum toxin screening assays |
US20050191321A1 (en) | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
GB2416692A (en) * | 2004-08-04 | 2006-02-08 | Ipsen Ltd | Pharmaceutical composition containing botulinum neurotoxin |
TR201708749T4 (tr) * | 2004-08-04 | 2018-03-21 | Ipsen Biopharm Ltd | Botuli̇num nörotoksi̇n a2 i̇çeren farmasöti̇k bi̇leşi̇m |
US7749515B2 (en) | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
US20090131480A1 (en) | 2005-04-04 | 2009-05-21 | Eisai Co., Ltd. | Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia |
US20100112005A1 (en) * | 2008-11-03 | 2010-05-06 | Solstice Neurosciences, Inc. | Compositions of activated botulinum toxin type B |
US20130236446A1 (en) | 2012-03-12 | 2013-09-12 | William J. Binder | Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth |
US8722060B2 (en) | 2012-05-23 | 2014-05-13 | William J. Binder | Method of treating vertigo |
-
2013
- 2013-05-10 US US14/410,010 patent/US20150231068A1/en not_active Abandoned
- 2013-05-10 ES ES17184030T patent/ES2759478T3/es active Active
- 2013-05-10 CA CA2867143A patent/CA2867143C/en active Active
- 2013-05-10 ES ES13760304.9T patent/ES2643507T3/es active Active
- 2013-05-10 EP EP17184030.9A patent/EP3257526B1/en active Active
- 2013-05-10 EP EP13760304.9A patent/EP2849781B1/en active Active
- 2013-05-10 MX MX2014010983A patent/MX358613B/es active IP Right Grant
- 2013-05-10 AU AU2013232758A patent/AU2013232758C1/en active Active
- 2013-05-10 WO PCT/US2013/000131 patent/WO2013137969A1/en active Application Filing
- 2013-05-10 DK DK13760304.9T patent/DK2849781T3/en active
-
2014
- 2014-09-10 ZA ZA2014/06598A patent/ZA201406598B/en unknown
-
2017
- 2017-04-28 US US15/582,407 patent/US10201497B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2014010983A (es) | 2017-07-21 |
US20150231068A1 (en) | 2015-08-20 |
EP3257526A1 (en) | 2017-12-20 |
US10201497B2 (en) | 2019-02-12 |
DK2849781T3 (en) | 2017-10-16 |
WO2013137969A1 (en) | 2013-09-19 |
EP2849781A4 (en) | 2015-04-15 |
CA2867143A1 (en) | 2013-09-19 |
EP2849781B1 (en) | 2017-09-13 |
ES2643507T3 (es) | 2017-11-23 |
AU2013232758A1 (en) | 2014-09-25 |
CA2867143C (en) | 2016-03-29 |
AU2013232758C1 (en) | 2015-03-05 |
ES2759478T3 (es) | 2020-05-11 |
EP2849781A1 (en) | 2015-03-25 |
US20170232080A1 (en) | 2017-08-17 |
EP3257526B1 (en) | 2019-10-16 |
AU2013232758B2 (en) | 2014-11-20 |
ZA201406598B (en) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014010983A (es) | Tratamiento de dolor de cabeza por migraña con neurotoxina presinaptica. | |
MX2020004183A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
PH12015502075B1 (en) | Treatment of cataplexy | |
MX2017004471A (es) | Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística. | |
MX2015005417A (es) | Composiciones y metodos para tratamiento seguro de la rinitis. | |
MX365950B (es) | Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica. | |
BR112015005227A2 (pt) | inibidores de glicosilceramida sintase | |
GB2503852A (en) | Compounds for the treatment of neuropsychiatric disorders | |
MX2016005446A (es) | Intervenciones a base de angiopoyetina para tratar la malaria cerebral. | |
BR112016018170A2 (pt) | métodos para tratar doença de alzheimer | |
MX2015003048A (es) | Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado. | |
EA201492279A1 (ru) | Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек | |
MX2014011270A (es) | Terapia de combinacion de un inhibidor de mek e inhibidor de igf1r. | |
PH12015501038A1 (en) | Inhibitors of iap | |
CA2881554C (en) | Methods for inhibiting fascin | |
TN2013000462A1 (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
PH12016500903A1 (en) | Novel methods for treating neurodegenerative diseases | |
MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
PH12014502065A1 (en) | Vesicular formulations | |
MX2017007245A (es) | Metodos de tratamiento de la fibrosis. | |
WO2014145498A3 (en) | Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase) | |
MD20140001A2 (ro) | Modulatori alosterici pozitivi ai receptorului nicotinic al acetilcolinei | |
AU2012240388A8 (en) | Treatment regimens | |
NZ629475A (en) | Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines | |
DOP2014000258A (es) | Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |